Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population

Phase 3

Withdrawn

Brief Summary: Secukinumab targets a different interleukin and has potential to be used as alternative to existing treatments. This study will provide clinical data with respect to efficacy through Psoriasis Area and Severity Index (PASI) at 16 weeks, safety/tolerability of secukinumab and evaluate the impact of the treatment on quality of life and work productivity in subjects with moderate to severe plaque psoriasis in the Turkish population.

Detailed Description: To demonstrate the efficacy of secukinumab in subjects with moderate to severe plaque psoriasis based on the percentage of PASI 90 responder patients at Week 16 as compared to baseline Evaluation of onset of efficacy measured by the percentage of patient achieving PASI 75 and PASI 90 at week 4 The efficacy of treatment using Investigator's Global Assessment modified 2011 (IGA mod 2011) at week 4 and week 16 Work productivity (measured with WPAI-PSO) at Week 16 Changes in quality of life measured with the Dermatology Life Quality Index (DLQI) at Week 16 Health assessment questionnaire -Disability index (HAQ-DI) in patients with psoriatic arthritis (PsA)

Recruitment & Eligibility

Inclusion Criteria

Subjects must be able to understand and comply with the requirements of the study and communicate with the investigator
Diagnosis of chronic plaque psoriasis for at least 6 months before enrollment
Patients who were evaluated as candidates for systemic therapy, defined as having psoriasis intolerant or /and inadequately controlled by: topical treatment (including topical corticosteroid) and/or phototherapy and/or any previous systemic treatment for psoriasis or any previous treatment with biologic agents

Exclusion Criteria

Forms of psoriasis other than plaque psoriasis
Drug-induced psoriasis
Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA
Pregnant or nursing (lactating) women
Active ongoing inflammatory diseases other than psoriasis or psoriatic arthritis that might confound the evaluation of the benefit of secukinumab
Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions)
Pre-existing or recent-onset central or peripheral nervous system demyelinating disorders
Significant medical problems, including but not limited to the following: uncontrolled hypertension, congestive heart failure
Active systemic infections during the 2 weeks prior to enrollment
History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection
Past medical history record of, or current infection with, human immunodeficiency virus (HIV), hepatitis B or hepatitis C prior to enrollment
History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years
History or evidence of ongoing alcohol or drug abuse, within the last 6 months prior to enrollment
Plans for administration of live vaccines during the study period or in the 6 weeks prior to enrollment
Not willing to limit UV light exposure

Arm && Interventions

Group	Intervention	Description
"Secukinumab" "Cosentyx TM"	"Secukinumab" "Cosentyx TM"	"Secukinumab" "Cosentyx TM" 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit. First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month

Primary Outcome Measures

Name	Time	Method
Percentage of PASI 90 responder patients at Week 16 as compared to baseline	16 week	The primary endpoint has been chosen as percentage of PASI 90 responder patients. PASI 90 is accepted as clear or almost clear of psoriatic lesions which are the ultimate goal of treatment in plaque psoriasis.

Secondary Outcome Measures

Name	Time	Method
The efficacy of treatment using Investigator's Global Assessment modified 2011 (IGA mod 2011) at week 4 and week 16	4 and 16 week	Investigator's Global Assessment (IGA mod 2011) score will be explained by using descriptive statistics at week 4 and week 16. Change between week 4 and week 16 comparing to baseline
Changes in quality of life measured with the Dermatology Life Quality Index (DLQI) at Week 16	16 week	Changes in quality of life measured with Dermatology Life Quality Index (DLQI) through visits will be evaluated by using Repeated Measures ANOVA test.
Health assessment questionnaire -Disability index (HAQ-DI) in patients with psoriatic arthritis (PsA)	16 week	Health Assessment Questionnaire-Disability Index (HAQ-DI) will be evaluated at all visits by using descriptive statistics. The change between visits will be evaluated by Repeated Measures ANOVA test.
Evaluation of onset of efficacy measured by the percentage of patient achieving PASI 75 and PASI 90 at week 4	4 week	Patients, who achieved PASI 75 and PASI 90 response at week 4 will be counted by using frequencies and percentages (a subject is defined as a PASI 90 responder if the PASI score is reduced by 90% or more compared to baseline visit)
Work productivity (measured with WPAI-PSO) at Week 16	16 week	Work productivity (WPAI-PSO) at week 16 will be evaluated by using descriptive statistics at week 16. Changes at work productivity through the visits will be inspected by using Repeated Measures ANOVA test.